Traxanox augments immune response to lipopolysaccharide in inbred mice: role of macrophages.
Both C57BL/6 and BALB/c mice were immunized intravenously with lipopolysaccharide (LPS, 10 micrograms/mouse) on day 0, and hemolytic plaque forming cells (HPFC) in the spleen were assayed on day 4. Traxanox given orally at a dose of 30 mg/kg augmented the HPFC production to LPS in both mice. This agent (3-30 mg/kg) restored significantly the suppressed HPFC production to LPS in the BALB/c mice pretreated with carrageenan (0.03 mg/mouse), but did not restore it in the BALB/c mice pretreated with cyclophosphamide (25 mg/kg). The transfer of spleen adherent cells of the mice immunized with LPS and treated with traxanox to the syngeneic mice resulted in a significant increase in the HPFC production to LPS. The HPFC production to trinitrophenylated polyvinylpyrrolidone, a T cell-independent antigen was not affected by the treatment with traxanox or carrageenan. These results suggest that traxanox has a capacity to augment the immune response by affecting macrophage function.
D000276:Adjuvants, Immunologic; D000818:Animals; D002867:Chromones / Q000494:pharmacology*; D004926:Escherichia coli / Q000276:immunology; D005260:Female; D008070:Lipopolysaccharides / Q000276:immunology*; D008264:Macrophages / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology
D000276:Adjuvants, Immunologic; D002867:Chromones; D008070:Lipopolysaccharides; C020178:traxanox